KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Assets (2016 - 2025)

Historic Return on Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to 0.07%.

  • Biomarin Pharmaceutical's Return on Assets rose 200.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.06% for FY2024, which is 400.0% up from last year.
  • Biomarin Pharmaceutical's Return on Assets amounted to 0.07% in Q3 2025, which was up 200.0% from 0.09% recorded in Q2 2025.
  • Biomarin Pharmaceutical's Return on Assets' 5-year high stood at 0.14% during Q2 2021, with a 5-year trough of 0.01% in Q4 2021.
  • For the 5-year period, Biomarin Pharmaceutical's Return on Assets averaged around 0.04%, with its median value being 0.02% (2023).
  • Over the last 5 years, Biomarin Pharmaceutical's Return on Assets had its largest YoY gain of 1200bps in 2021, and its largest YoY loss of -1500bps in 2021.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Return on Assets stood at 0.01% in 2021, then surged by 309bps to 0.02% in 2022, then grew by 10bps to 0.02% in 2023, then soared by 150bps to 0.06% in 2024, then increased by 12bps to 0.07% in 2025.
  • Its Return on Assets was 0.07% in Q3 2025, compared to 0.09% in Q2 2025 and 0.07% in Q1 2025.